Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Stopped Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to include this study of TP-0903.

Conditions

• Chronic Lymphocytic Leukemia
• CLL
• SLL
• Small Lymphocytic Lymphoma

Interventions

• DRUG: TP-0903
• COMBINATION_PRODUCT: TP-0903 and ibrutinib combination therapy

Sponsor

Sumitomo Pharma America, Inc.